In contrast, gene editing approaches, demonstrated for FVIII in our study and for Factor IX by Ohmori et al. 36 and Sangamo Therapeutics (using zinc finger nucleases), can potentially offer a life-time cure for hemophilia patients. Here, F9 is linked to hemophilia.